US Tariffs Fatal for European Pharma
Trump's tariff policy is a considerable burden and a break with previous practice.
Novartis
11.02.2025 • News
Novartis to Acquire Anthos Therapeutics
Swiss drugmaker Novartis has agreed to acquire Anthos Therapeutics, a Boston, US-based biopharmaceutical company with its lead compound abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
22.11.2024 • News
Novartis Acquires Kate Therapeutics for $1.1 Billion
Swiss pharmaceutical giant Novartis has acquired Kate Therapeutics for $1.1 billion. The San Diego, US-headquartered preclinical stage biotechnology company develops adeno-associated virus (AAV)-based gene therapies to treat inherited neuromuscular diseases.
23.08.2024 • News
Novartis and Versant Launch Borealis Biosciences
Novartis announced it has partnered with Versant Ventures to form Borealis Biosciences, an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused on developing next-generation xRNA-based medicines for kidney diseases.
26.07.2024 • News
Dren Bio, Novartis to Develop Bispecific Cancer Antibodies
US biopharmaceutical company Dren Bio, a developer of novel antibody therapeutics, has entered into a collaboration with Novartis Pharma, a subsidiary of Novartis. The collaboration will focus on the discovery and development of therapeutic bispecific antibodies for cancer using Dren Bio’s proprietary targeted myeloid engager and phagocytosis platform.
03.05.2024 • News
Novartis to Acquire Mariana Oncology
Swiss drugmaker Novartis agreed to acquire Mariana Oncology, a US biotechnology company based in Watertown, Massachusetts, that develops novel radioligand therapies (RLTs) for the treatment of cancer.
Integrated Continuous Manufacturing in Pharmaceuticals
An innovative manufacturing platform called integrated continuous manufacturing (ICM) represents a completely modernized model for drug manufacturing. In contrast to batch processes, ICM’s unique operational advantages will allow for cost-competitive end-to-end manufacturing and enable a more robust and responsive supply chain for critical drugs.
10.01.2024 • News
Isomorphic Labs to Collaborate with Eli Lilly and Novartis
Isomorphic Labs announced strategic collaborations with leading pharmaceutical companies, Eli Lilly and Company and Novartis. These partnerships have the potential to be worth nearly €2.75 billion ($3 billion) to Isomorphic Labs, excluding any royalties that may result from future drug sales. Both collaborations are multi-target, focused on small molecules, and include a combination of upfront and milestone payments.
25.09.2023 • News
Sandoz Spin-off from Novartis to Start on October 4, 2023
Novartis today confirmed the plan to spin off 100% of its generic drugs arm Sandoz, with trading of the new company’s shares as well as ADRs (American Depositary Receipts) to start on Oct. 4, 2023.
03.07.2023 • News
Novartis Divests Ophthalmology Assets to Bausch + Lomb for Up to $2.5 Billion
Novartis has signed an agreement to divest its 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company. The transaction is valued at up to $2.5 billion, which marks a strategic move to focus on innovative medicines and growth opportunities.
12.05.2023 • News
Sandoz in Biosimilars Pact with Just – Evotec Biologics
As Novartis moves toward shedding generics subsidiary Sandoz, which it touts as a global leader in off-patent generic and biosimilar drugs, Sandoz has agreed a multi-year strategic partnership with Just –Evotec Biologics, the Seattle, Washington-based US subsidiary of Germany’s Evotec, to develop and manufacture biosimilars.
22.03.2023 • News
Sangamo Reviews Options as Drugmakers Terminate Deals
US biotech Sangamo Therapeutics is studying alternative options to advance its neurological disease programs after both Novartis and Biogen ended their respective collaborations. The California-based company said options could include potentially developing the programs internally, or with another partner.
17.03.2023 • News
Sandoz Builds Biologics Plant in Slovenia
Sandoz, the generics and biosimilars arm of Swiss drugmaker Novartis, has signed a Memorandum of Understanding to build a biologics production plant in Lendava, Slovenia.
31.01.2023 • News
EMA Reviewing Approval of Novartis’ Adakveo
The European Medicines Agency (EMA) said its Committee for Medicinal Products for Human Use (CHMP) has begun reviewing its marketing authorization for Novartis’ Adakveo, a medicine to prevent vaso-occlusive pain crises in patients with sickle cell disease.
05.01.2023 • News
Novartis to Pay $245 Million in ’Pay for Delay’ Settlement
Novartis has agreed to pay a total of $245 million to settle lawsuits filed by direct purchasers, indirect purchasers and retailers accusing it of colluding with Par Pharmaceutical to delay the launch of a generic version of its Exforge (valsartan/amlodipine) hypertension drug.
22.12.2022 • News
Jobs to Go at Novartis US Headquarters
As part of plans, announced in dribbles, to carve 8,000 jobs out of its global workforce to save $1 billion, Swiss drugs giant Novartis is eliminating 285 staff positions across its headquarters sites in the US state of New Jersey.
15.11.2022 • News
BioNTech Buys Novartis Singapore Plant for Asia HQ
German Covid-19 vaccine specialist BioNTech has acquired a production facility in Singapore from Swiss drugmaker Novartis that will serve as a manufacturing base in addition to being its Asia-Pacific headquarters.
09.11.2022 • News
Sandoz Invests in Extra European Antibiotic Capacity
Sandoz, the generics arm of Swiss drugmaker Novartis, has announced plans to spend an additional €50 million on raising European manufacturing capacity for finished dosage forms of amoxicillin and other key penicillin products.
18.10.2022 • Topics • Technology
AI Maturity Model for GxP Application
Artificial intelligence (AI) has become one of the supporting pillars for digitalization in many areas of the business world. The pharmaceutical industry and its GxP-regulated areas also want to use AI in a beneficial way, but only a small fraction of companies follows a systematic approach for the digitalization of their operations and validation. However, the assurance of integrity and quality of outputs via computerized system validation is essential for applications in GxP environments.
09.09.2022 • News
Novartis to Shutter a Sandoz US Plant
In advance of the planned spinoff of generics subsidiary Sandoz into a standalone generics producer, Novartis has announced it is closing one of the subsidiary’s US plants.
06.09.2022 • News
Novartis Sued over its own Drug
Swiss drugmaker Novartis, already embroiled in a number of lawsuits against generics producers seeking to create copies of its blockbuster cardiac insufficiency treatment Entresto, is now itself being sued.
29.08.2022 • News
Novartis Definitely Plans to Spin off Sandoz
Novartis has finally confirmed definite plans to spin off its generic drugs arm Sandoz.
29.06.2022 • News
Novartis Confirms 8,000 Global Jobs Will be Axed
Novartis has confirmed reports by Swiss daily newspaper Tages-Anzeiger that it plans to slash 8,000 jobs worldwide.
28.06.2022 • News
Novartis Pledges to Fight Tropical Diseases and Malaria
Swiss drugmaker Novartis has made a five-year financial commitment of $250 million to fight neglected tropical diseases (NTDs) and malaria.
13.06.2022 • News
Samsung Biologics in $81 Million Deal with Novartis
In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development deal, Samsung said in a regulatory filing.
19.04.2022 • News
Sandoz Launches Generic Combigan Drops
Novartis subsidiary Sandoz has launched a generic version of Combigan, the ocular hypertensiondrug made by AbbVie’s Allergan arm. The copy of the off-patent eye drops will be marketed only in the US, where Allergan racked up sales of $373 million with the original product in 2021.
05.04.2022 • News
Novartis Creates new Innovative Medicines Unit
Swiss pharma powerhouse Novartis is merging its pharmaceuticals and oncology businesses into a new unit called Innovative Medicines (IM). The restructuring that will create separate US and International commercial organizations is expected to increase focus, strengthen competitiveness and drive synergies in high-value medicines.
22.02.2022 • News
Novartis Takes Gyroscope Therapeutics for $1.5 Billion
Swiss pharma Novartis has acquired Gyroscope Therapeutics, a clinical-stage gene therapy company focused on diseases of the eye, from Syncona, a UK-based firm that says it focuses on founding and building businesses with exceptional science in areas of high unmet medical need.
02.02.2022 • News
Private Equity Buyers Seen as Circling Sandoz
US private equity firms Blackstone and Carlyle may make a joint offer for the Novartis generics unit Sandoz, Bloomberg reports. With six other possible bidders seen as circling Basel-based Sandoz, the news agency’s sources said this sale could shape up to be one of the biggest-ever buyout deals, valued at around $25 billion.
14.12.2021 • News
Novartis May Have Sandoz Buyer on the Hook
Novartis and market watchers alike have been dropping repeated hits that a sale of the Swiss drugs giant’s Sandoz-branded generic drugs arm may be closer than has been hinted up to now. In an interview with German weekly news magazine Wirtschaftswoche last week, CEO Vas Narasimhan said, however, that beyond several requests for information no concrete offers are currently on the table.
08.11.2021 • News
Novartis Selling Roche Shares Back to Swiss Rival
In the reverse of a deal sealed 20 years ago, Novartis is selling the 33% stake it bought in Roche back to the compatriot drugmaker. The latest transaction between the two Swiss giants sees 53.3 million shares moving across Basel again for a much higher price of $20.7 billion.
30.09.2021 • News
Novartis Boosts Ophthalmology with Arctos Medical Buy
Swiss drugmaker Novartis has acquired Arctos Medical, a compatriot start-up developing optogenetic therapies. Financial terms of the deal were not disclosed.
15.09.2021 • News
The Transition to Digitalization in the Pharmaceutical Industry
ISPE and its members are developing the roadmap to introduce Industry 4.0, also called the Smart Factory, at the pharmaceutical industry as Pharma 4.0 – an operating model that is interconnected, meaning that the digital tools allow for a fully connected network to enable direct communication between all levels in an organization.
06.09.2021 • News
Expert Statement: Markus Zeitz, Novartis
ISPE and its members are developing the roadmap to introduce Industry 4.0, also called the Smart Factory, at the pharmaceutical industry as Pharma 4.0 – an operating model that is interconnected, meaning that the digital tools allow for a fully connected network to enable direct communication between all levels in an organization.
11.05.2021 • News
BASF Invests in Enzymes in Austria
BASF is investing in its enzymes business at the Novartis Kundl/Schaftenau Campus in Austria. The German chemical giant said the agreement with the Swiss group – for which financial details were not disclosed – will enable it to develop a world-scale operation for bacterial enzymes and biotechnology products.
KPMG
ACIB Austrian Centre of Industrial Biotechnology
Novartis Vaccines and Diagnostics GmbH & Co.KG
Microinnova Engineering GmbH
Novartis International AG
Chemical Market Reporter
EvaluatePharma
F. Hoffmann-La Roche Ltd
SchüllerConsulting
Isomorphic Labs
Camelot Management Consultants AG
Frost & Sullivan
CONTINUUS Pharmaceuticals, Inc.
Oracle Germany
Styron Europe GmbH
ISPE D/A/CH e.V.
Thomson Reuters
Scienceindustries - Wirtschaftsverband Chemie Pharma Life Sciences
GETEC Group
CHEManager International c/o Wiley-VCH GmbH
GlobalData
Merck KGaA
Novartis Pharma GmbH
Arthur D. Little